Adheris Health Limited (ASX:AHE)
Australia
· Delayed Price · Currency is AUD | Market Cap | 12.11M |
| Revenue (ttm) | 40.60M |
| Net Income (ttm) | -54.26M |
| Shares Out | 637.15M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,370,924 |
| Average Volume | 436,272 |
| Open | 0.0180 |
| Previous Close | 0.0190 |
| Day's Range | 0.0170 - 0.0230 |
| 52-Week Range | 0.0170 - 0.1650 |
| Beta | 0.96 |
| RSI | 46.11 |
| Earnings Date | Apr 28, 2026 |
About Adheris Health
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts. [Read more]
Financial Performance
Financial StatementsNews
Adheris Health Transcript: AGM 2025
The meeting addressed a challenging year marked by a statutory loss, ANZ divestiture, and U.S. revenue decline. Strategic priorities include cost reduction, digital expansion, and product innovation. All resolutions were put to a poll, with results to be announced to the ASX.
Adheris Health Earnings Call Transcript: Q1 2026
Q1 saw significant revenue and margin declines due to regulatory delays, policy pressures, and market headwinds, especially in vaccines. The business is now focused on U.S. transformation, cost optimization, and digital innovation, with specialty medications expected to drive future growth.
Adheris Health Transcript: AGM 2025
The meeting addressed 14 resolutions, with notable shareholder protest votes against executive incentives and retention benefits. Key risks discussed included executive retention and morale, with the Chair emphasizing transparency and the need for stability during strategic changes.
Adheris Health Earnings Call Transcript: Q4 2025
FY 2025 results were impacted by U.S. program delays and industry headwinds, leading to a revenue decline and revised guidance. The ANZ business was sold, strengthening the balance sheet, while FY 2026 targets 15% revenue growth and reduced costs amid ongoing strategic review.
Adheris Health Transcript: Investor Update
A strategic review led to the sale of the ANZ business for up to AUD 42.35 million, eliminating debt and leaving a strong cash position. The U.S. business is now the focus, with ongoing review and growth initiatives, and the Board is considering capital management options.
Adheris Health Earnings Call Transcript: Q3 2025
Revenue and gross profit fell sharply in 3Q FY25 due to U.S. headwinds, but cost reductions and a strong ANZ business underpin a positive outlook. Strategic review and new platform initiatives are expected to drive growth and margin expansion in FY26.
Half Year 2025 MedAdvisor Ltd Earnings Presentation Transcript
Half Year 2025 MedAdvisor Ltd Earnings Presentation Transcript
Adheris Health Earnings Call Transcript: H1 2025
First half FY25 revenue declined due to lower US vaccine-related pharma spend, but profitability was maintained and gross margin improved. Transformation 360 restructuring and a strategic review are underway, with a strong pipeline and new platform launches expected in the second half.
Adheris Health Earnings Call Transcript: Q2 2025
Revenue and gross profit declined sharply due to U.S. vaccine program delays, but gross margin improved from a favorable product mix. Restructuring and SaaS pricing changes are expected to drive cost savings and revenue growth in H2, with a positive full-year EBITDA outlook.
Adheris Health Transcript: AGM 2024
The meeting highlighted record revenue and first profit, a refreshed board, and a five-year plan aiming to double revenue by 2028. Strategic initiatives include a cloud-based platform, AI integration, and a formal review to maximize shareholder value. Voting on five resolutions was conducted by poll.